Keller Steven P
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ann Cardiothorac Surg. 2020 Jan;9(1):29-41. doi: 10.21037/acs.2019.12.03.
The introduction of the lung allocation score in 2005 prioritized patients with decreased transplant-free survival as the recipients of donor organs and effectively increased the number of critically-ill patients with end-stage lung disease waiting for transplantation. This change presented transplant programs with the challenge of how to both extend the lives of critically-ill, end-stage lung disease patients waiting for donor organs and maintain patient vitality to survival through the rigors of surgery and post-transplant recovery. Motivated by the dismal outcomes of patients maintained on mechanical ventilation pre-transplant, transplant centers increasingly deploy extracorporeal membrane oxygenation (ECMO) as a means of supporting patients with advanced disease as a bridge to successful lung transplantation. ECMO is an extracorporeal gas exchange device providing delivery of oxygen and removal of carbon dioxide from blood passed through the circuit. The specific cannulation strategy determines whether ECMO provides primarily respiratory or circulatory support. The cannulation approach is tailored to the specific physiological manifestations of the pre-lung transplant candidate's disease process. For patients with profound hypoxic respiratory failure, a cannulation strategy that captures a large fraction of the venous return is required to maintain adequate support whereas lower circuit flows are sufficient for patients with predominantly hypercapnic respiratory failure. Improving outcomes and increasing experience with ECMO is motivating transplant centers to initiate support before patients require mechanical ventilation. Awake cannulation is increasingly common and is used to avoid the complications associated with intubation in advanced lung failure. Determining criteria for initiation of support and identifying the optimal approach to support patients with right heart failure in need of circulatory support are avenues of active investigation. Use of ECMO and other forms of extracorporeal support are rapidly becoming a mainstay in the care of the pre-lung transplant patient with advanced disease.
2005年引入的肺分配评分系统将移植后无生存时间缩短的患者列为优先接受供体器官的对象,这有效地增加了等待移植的终末期肺病重症患者的数量。这一变化给移植项目带来了挑战,即如何在延长等待供体器官的终末期肺病重症患者生命的同时,通过严格的手术和移植后恢复过程维持患者的生存活力。鉴于移植前接受机械通气的患者预后不佳,移植中心越来越多地采用体外膜肺氧合(ECMO)作为支持晚期疾病患者的手段,作为成功肺移植的桥梁。ECMO是一种体外气体交换装置,可从通过该回路的血液中输送氧气并去除二氧化碳。具体的插管策略决定了ECMO主要提供呼吸支持还是循环支持。插管方法是根据肺移植前候选患者疾病过程的特定生理表现量身定制的。对于严重低氧性呼吸衰竭患者,需要一种能够捕获大部分静脉回流的插管策略来维持足够的支持,而对于主要为高碳酸血症性呼吸衰竭患者,较低的回路流量就足够了。改善预后和增加ECMO使用经验促使移植中心在患者需要机械通气之前就开始提供支持。清醒插管越来越普遍,用于避免晚期肺衰竭患者插管相关的并发症。确定开始支持的标准以及确定支持需要循环支持的右心衰竭患者的最佳方法是当前积极研究的方向。ECMO和其他形式的体外支持的使用正迅速成为晚期疾病肺移植前患者护理的主要手段。